These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
357 related articles for article (PubMed ID: 19440560)
21. An Indian effort towards affordable drugs: "generic to designer drugs". Taneja B; Yadav J; Chakraborty TK; Brahmachari SK Biotechnol J; 2009 Mar; 4(3):348-60. PubMed ID: 19296440 [No Abstract] [Full Text] [Related]
22. The Eleventh Circuit holds that agreements in which pharmaceutical companies pay generic companies not to compete may be valid. Garrigues A J Law Med Ethics; 2004; 32(1):181-4. PubMed ID: 15152443 [No Abstract] [Full Text] [Related]
23. Indian generics companies go on spending spree. Jayaraman KS Nat Rev Drug Discov; 2005 Aug; 4(8):616-7. PubMed ID: 16106583 [No Abstract] [Full Text] [Related]
24. Originator drug development. Findlay RJ Food Drug Law J; 1999; 54(2):227-32. PubMed ID: 11758577 [No Abstract] [Full Text] [Related]
25. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering. Paine CS Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807 [No Abstract] [Full Text] [Related]
26. The strategic response by pharmaceutical firms to the Medicaid most-favored-customer rules. Scott Morton F Rand J Econ; 1997; 28(2):269-90. PubMed ID: 11794358 [TBL] [Abstract][Full Text] [Related]
27. Ownership of knowledge--the role of patents in pharmaceutical R&D. Correa CM Bull World Health Organ; 2004 Oct; 82(10):784-7; discussion 787-90. PubMed ID: 15643801 [TBL] [Abstract][Full Text] [Related]
28. Overcoming the obstacles in the pharma/biotech industry: 2008 update. Graul AI; Revel L; Rosa E; Cruces E Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298 [TBL] [Abstract][Full Text] [Related]
29. Competition between brand-name and generics--analysis on pricing of brand-name pharmaceutical. Kong Y Health Econ; 2009 May; 18(5):591-606. PubMed ID: 18816580 [TBL] [Abstract][Full Text] [Related]
30. International Generic Pharmaceutical Alliance - 12th Annual Conference. Part 1. Kuhrt K; Chace-Ortiz M IDrugs; 2009 Dec; 12(12):760-4. PubMed ID: 19943217 [TBL] [Abstract][Full Text] [Related]
31. A shift on "pay for delay"--reopening doors for pharmaceutical competition? Hemphill Kraus EJ N Engl J Med; 2012 Nov; 367(18):1681-3. PubMed ID: 23113478 [No Abstract] [Full Text] [Related]
32. Selling Patents to Indian Tribes to Delay the Market Entry of Generic Drugs. Ablavsky G; Larrimore Ouellette L JAMA Intern Med; 2018 Feb; 178(2):179-180. PubMed ID: 29297039 [No Abstract] [Full Text] [Related]
34. The new drug war. Sherrid P US News World Rep; 2002 Dec; 133(21):41. PubMed ID: 12503485 [No Abstract] [Full Text] [Related]
35. Insulin has never become a cheap generic drug in the US because of companies' small changes to "evergreen" the patent. Mayor S BMJ; 2015 Mar; 350():h1535. PubMed ID: 25794503 [No Abstract] [Full Text] [Related]
36. Drug patent expirations and the speed of generic entry. Bae JP Health Serv Res; 1997 Apr; 32(1):87-101. PubMed ID: 9108806 [TBL] [Abstract][Full Text] [Related]
37. The GO License: only part of the solution. Batson A; Milstien JB Health Aff (Millwood); 2008; 27(1):140-2. PubMed ID: 18180489 [TBL] [Abstract][Full Text] [Related]
38. Patent cliff mitigation strategies: giving new life to blockbusters. Kakkar AK Expert Opin Ther Pat; 2015; 25(12):1353-9. PubMed ID: 26372691 [TBL] [Abstract][Full Text] [Related]
39. Striking the right balance between innovation and drug price competition: understanding the Hatch-Waxman Act--an introduction of speakers. Rea TS Food Drug Law J; 1999; 54(2):223-5. PubMed ID: 11759713 [No Abstract] [Full Text] [Related]
40. Pharmaceutical R&D: an age of change? Baldwin JJ Future Med Chem; 2014 Jun; 6(10):1109-12. PubMed ID: 25078132 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]